Idiopathic intracranial hypertension (IIH), or pseudotumor cerebri, is a condition of elevated intracranial pressure in the absence of clinical, laboratory or radiological evidence of an intracranial space occupying lesion that can occur in the pediatric population. While IIH is more commonly recognized as a disorder of adults, it affects children of all ages and can have distinctive characteristics when presenting in the prepubertal age group. This review discusses the demographics, clinical presentation, diagnosis, neuroimaging, and management of pediatric IIH. Common etiologies of IIH in children, with particular focus on endocrine abnormalities, are highlighted.

Keywords:
Papilledema, Pediatric pseudotumor cerebri, Pediatric idiopathic intracranial hypertension
1.
Friedman DI, Jacobson DM: Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002;59:1492–1495.
2.
Durcan FJ, Corbett JJ, Wall M: The incidence of pseudotumor cerebri: population studies in iowa and louisiana. Arch Neurol 1988;45:875–877.
3.
Radhakrishnan K, Ahlskog JE, Cross SA, Kurland LT, O’Fallon WM: Idiopathic intracranial hypertension (pseudotumor cerebri).Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 1993;50:78–80.
4.
Babikian P, Corbett J, Bell W: Idiopathic intracranial hypertension in children: the Iowa experience. J Child Neurol 1994;9:144–149.
5.
Baker RS, Baumann RJ, Buncic JR: Idiopathic intracranial hypertension (pseudotumor cerebri) in pediatric patients. Pediatr Neurol 1989;5:5–11.
6.
Lessell S: Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). Surv Ophthalmol 1992;37:155–166.
7.
McKiernan SP, DiFazio MP: Index of suspicion. Case 3. Diagnosis: infantile pseudotumor cerebri. Pediatr Rev 2001;22:211–215.
8.
Gordon K: Pediatric pseudotumor cerebri: descriptive epidemiology. Can J Neurol Sci 1997;24:219–221.
9.
Distelmaier F, Sengler U, Messing-Juenger M, Assmann B, Mayatepek E, Rosenbaum T: Pseudotumor cerebri as an important differential diagnosis of papilledema in children. Brain Dev 2006;28:190–195.
10.
Cinciripini GS, Donahue S, Borchert MS: Idiopathic intracranial hypertension in prepubertal pediatric patients: characteristics, treatment, and outcome. Am J Ophthalmol 1999;127:178–182.
11.
Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.
12.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23.
13.
Rangwala LM, Liu GT: Pediatric idiopathic intracranial hypertension. Surv Ophthalmol 2007;52:597–617.
14.
Avery RH, Shah SS, Licht DJ, Seiden JA, Huh JW, Boswinkel J, Ruppe MD, Chew A, Mistry RD, Liu GT: Reference range of cerebrospinal fluid opening pressure in children undergoing diagnostic lumbar puncture. N Engl J Med 2010;363:891–893.
15.
Rowe FJ, Sarkies NJ: The relationship between obesity and idiopathic intracranial hypertension. Int J Obes Relat Metab Disord 1999;23:54–59.
16.
Scott IU, Siatkowski RM, Eneyni M, Brodsky MC, Lam BL: Idiopathic intracranial hypertension in children and adolescents. Am J Ophthalmol 1997;124:253–255.
17.
Balcer LJ, Liu GT, Forman S, Pun K, Volpe NJ, Galetta SL, Maguire MG: Idiopathic intracranial hypertension: relation of age and obesity in children. Neurology 1999;52:870–872.
18.
Phillips PH, Repka MX, Lambert SR: Pseudotumor cerebri in children. J AAPOS 1998;2:33–38.
19.
Soler D, Cox T, Bullock P, Calver DM, Robinson RO: Diagnosis and management of benign intracranial hypertension. Arch Dis Child 1998;78:89–94.
20.
Lim M, Kurian M, Penn A, Calver D, Lin JP: Visual failure without headache in idiopathic intracranial hypertension. Arch Dis Child 2005;90:206–210.
21.
Salman MS, Kirkham FJ, MacGregor DL: Idiopathic ‘benign’ intracranial hypertension: case series and review. J Child Neurol 2001;16:465–470.
22.
Kesler A, Fattal-Valevski A: Idiopathic intracranial hypertension in the pediatric population. J Child Neurol 2002;17:745–748.
23.
Weig SG: Asymptomatic idiopathic intracranial hypertension in young children. J Child Neurol 2002;17:239–241.
24.
Johnston IH, Duff J, Jacobson EE, Fagan E: Asymptomatic intracranial hypertension in disorders of CSF circulation in childhood–treated and untreated. Pediatr Neurosurg 2001;34:63–72.
25.
Winner P, Bello L: Idiopathic intracranial hypertension in a young child without visual symptoms or signs. Headache 1996;36:574–576.
26.
Youroukos S, Psychou F, Fryssiras S, Paikos P, Nicolaidou P: Idiopathic intracranial hypertension in children. J Child Neurol 2000;15:453–457.
27.
Suzuki H, Takanashi J, Kobayashi K, Nagasawa K, Tashima K, Kohno Y: MR imaging of idiopathic intracranial hypertension. AJNR Am J Neuroradiol 2001;22:196–199.
28.
Speer C, Pearlman J, Phillips PH, Cooney M, Repka MX: Fourth cranial nerve palsy in pediatric patients with pseudotumor cerebri. Am J Ophthalmol 1999;127:236–237.
29.
Capobianco DJ, Brazis PW, Cheshire WP: Idiopathic intracranial hypertension and seventh nerve palsy. Headache 1997;37:286–288.
30.
Adams C, Dean HJ, Israels SJ, Patton A, Fewer DH: Primary hypothyroidism with intracranial hypertension and pituitary hyperplasia. Pediatr Neurol 1994;10:166–168.
31.
Krishna R, Kosmorsky GS, Wright KW: Pseudotumor cerebri sine papilledema with unilateral sixth nerve palsy. J Neuroophthalmol 1998;18:53–55.
32.
Liu GT, Volpe NJ, Galetta S: Neuro-ophthalmology: diagnosis and management. Philadelphia, Saunders, 2001.
33.
Karahalios DG, Rekate HL, Khayata MH, Apostolides PJ: Elevated intracranial venous pressure as a universal mechanism in pseudotumor cerebri of varying etiologies. Neurology 1996;46:198–202.
34.
Baryshnik DB, Farb RI: Changes in the appearance of venous sinuses after treatment of disordered intracranial pressure. Neurology 2004;62:1445–1446.
35.
McGonigal A, Bone I, Teasdale E: Resolution of transverse sinus stenosis in idiopathic intracranial hypertension after L-P shunt. Neurology 2004;62:514–515.
36.
Higgins JN, Pickard JD: Lateral sinus stenoses in idiopathic intracranial hypertension resolving after CSF diversion. Neurology 2004;62:1907–1908.
37.
Campos SP, Olitsky S: Idiopathic intracranial hypertension after L-thyroxine therapy for acquired primary hypothyroidism. Clin Pediatr (Phila) 1995;34:334–337.
38.
Raghavan S, DiMartino-Nardi J, Saenger P, Linder B: Pseudotumor cerebri in an infant after L-thyroxine therapy for transient neonatal hypothyroidism. J Pediatr 1997;130:478–480.
39.
Van Dop C, Conte FA, Koch TK, Clark SJ, Wilson-Davis SL, Grumbach MM: Pseudotumor cerebri associated with initiation of levothyroxine therapy for juvenile hypothyroidism. N Engl J Med 1983;308:1076–1080.
40.
Merkenschlager A, Ehrt O, Muller-Felber W, Schmidt H, Bernhard MK: Reversible benign intracranial hypertension in a child with hyperthyroidism. J Pediatr Endocrinol Metab 2008;21:1099–1101.
41.
Liu GT, Kay MD, Bienfang DC, Schatz NJ: Pseudotumor cerebri associated with corticosteroid withdrawal in inflammatory bowel disease. Am J Ophthalmol 1994;117:352–357.
42.
Levine A, Watemberg N, Hager H, Bujanover Y, Ballin A, Lerman-Sagie T: Benign intracranial hypertension associated with budesonide treatment in children with crohn’s disease. J Child Neurol 2001;16:458–461.
43.
Alexandrakis G, Filatov V, Walsh T: Pseudotumor cerebri in a 12-year-old boy with Addison’s disease. Am J Ophthalmol 1993;116:650–651.
44.
Condulis N, Germain G, Charest N, Levy S, Carpenter TO: Pseudotumor cerebri: a presenting manifestation of Addison’s disease. Clin Pediatr (Phila) 1997;36:711–713.
45.
Saenger P: Metabolic consequences of growth hormone treatment in paediatric practice. Horm Res 2000;53(suppl 1):60–69.
46.
Reeves GD, Doyle DA: Growth hormone treatment and pseudotumor cerebri: coincidence or close relationship? J Pediatr Endocrinol Metab 2002;15(suppl 2):723–730.
47.
Clayton PE, Cowell CT: Safety issues in children and adolescents during growth hormone therapy: a review. Growth Horm IGF Res 2000;10:306–317.
48.
Malozowski S, Tanner LA, Wysowski D, Fleming GA: Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. N Engl J Med 1993;329:665–666.
49.
Blethen SL: Complications of growth hormone therapy in children. Curr Opin Pediatr 1995;7:466–471.
50.
Koller EA, Stadel BV, Malozowski SN: Papilledema in 15 renally compromised patients treated with growth hormone. Pediatr Nephrol 1997;11:451–454.
51.
Johansson JO, Larson G, Andersson M, Elmgren A, Hynsjo L, Lindahl A, Lundberg PA, Isaksson OG, Lindstedt S, Bengtsson BA: Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinology 1995;61:57–66.
52.
Crock PA, McKenzie JD, Nicoll AM, Howard NJ, Cutfield W, Shield LK, Byrne G: Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand. Acta Paediatr 1998;87:381–386.
53.
Collett-Solberg PF, Liu GT, Satin-Smith M, Katz LL, Moshang T, Jr: Pseudopapilledema and congenital disc anomalies in growth hormone deficiency. J Pediatr Endocrinol Metab 1998;11:261–265.
54.
Alder JB, Fraunfelder FT, Edwards R: Levonorgestrel implants and intracranial hypertension. N Engl J Med 1995;332:1720–1721.
55.
Neely DE, Plager DA, Kumar N: Desmopressin (DDAVP)-induced pseudotumor cerebri. J Pediatr 2003;143:808.
56.
Mehta V, Chapman A, McNeely PD, Walling S, Howes WJ: Latency between symptom onset and diagnosis of pediatric brain tumors: an eastern Canadian geographic study. Neurosurgery 2002;51:365–372; discussion 372–363.
57.
Suwanwela N, Phanthumchinda K, Kaoropthum S: Headache in brain tumor: a cross-sectional study. Headache 1994;34:435–438.
58.
Antunes NL: The spectrum of neurologic disease in children with systemic cancer. Pediatr Neurol 2001;25:227–235.
59.
Chateil JF, Dousset V, Meyer P, Pedespan JM, San-Galli F, Rivel J, Caille JM, Diard F: Cranial aneurysmal bone cysts presenting with raised intracranial pressure: report of two cases. Neuroradiology 1997;39:490–494.
60.
Said RR, Rosman NP: A negative cranial computed tomographic scan is not adequate to support a diagnosis of pseudotumor cerebri. J Child Neurol 2004;19:609–613.
61.
Ozsvath RR, Casey SO, Lustrin ES, Alberico RA, Hassankhani A, Patel M: Cerebral venography: comparison of CT and MR projection venography. Ajr 1997;169:1699–1707.
62.
Kaiser AM, Whitelaw AG: Normal cerebrospinal fluid pressure in the newborn. Neuropediatrics 1986;17:100–102.
63.
Kestenbaum LA, Ebberson J, Zorc JJ, Hodinka RL, Shah SS: Defining cerebrospinal fluid white blood cell count reference values in neonates and young infants. Pediatrics;125:257–264.
64.
Fishman RA: Cerebrospinal Fluid in Diseases of the Nervous System, ed 2. Philadelphia, Saunders, 1992.
65.
Johnson LN, Krohel GB, Madsen RW, March GA Jr: The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998;105:2313–2317.
66.
Schoeman JF: Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol 1994;9:130–134.
67.
Finsterer J, Földy D, Fertl E, Rudolfstiftung K: Topiramate resolves headache from pseudotumor cerebri. J Pain Symptom Manage 2006;32:401–402.
68.
Thompson PJ, Baxendale SA, Duncan JS, Sander JW: Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69:636–641.
69.
Liu GT, Glaser JS, Schatz NJ: High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri. Am J Ophthalmol 1994;118:88–96.
70.
Friedman DI, Rausch EA: Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology 2002;58:1551–1553.
71.
Mathew NT, Ravishankar K, Sanin LC: Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology 1996;46:1226–1230.
72.
Thuente DD, Buckley EG: Pediatric optic nerve sheath decompression. Ophthalmology 2005;112:724–727.
73.
Lee AG, Patrinely JR, Edmond JC: Optic nerve sheath decompression in pediatric pseudotumor cerebri. Ophthalmic Surg Lasers 1998;29:514–517.
74.
Goh KY, Schatz NJ, Glaser JS: Optic nerve sheath fenestration for pseudotumor cerebri. J Neuro-ophthalmol 1997;17:86–91.
75.
Mauriello JA, Jr, Shaderowfsky P, Gizzi M, Frohman L: Management of visual loss after optic nerve sheath decompression in patients with pseudotumor cerebri. Ophthalmology 1995;102:441–445.
76.
Kelman SE, Heaps R, Wolf A, Elman MJ: Optic nerve decompression surgery improves visual function in patients with pseudotumor cerebri. Neurosurgery 1992;30:391–395.
77.
Rekate HL, Wallace D: Lumboperitoneal shunts in children. Pediatr Neurosurg 2003;38:41–46.
78.
Chumas PD, Kulkarni AV, Drake JM, Hoffman HJ, Humphreys RP, Rutka JT: Lumboperitoneal shunting: a retrospective study in the pediatric population. Neurosurgery 1993;32:376–383; discussion 383.
79.
Eggenberger ER, Miller NR, Vitale S: Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology 1996;46:1524–1530.
80.
Burgett RA, Purvin VA, Kawasaki A: Lumboperitoneal shunting for pseudotumor cerebri. Neurology 1997;49:734–739.
81.
Rosenberg ML, Corbett JJ, Smith C, Goodwin J, Sergott R, Savino P, Schatz N: Cerebrospinal fluid diversion procedures in pseudotumor cerebri. Neurology 1993;43:1071–1072.
82.
Bynke G, Zemack G, Bynke H, Romner B: Ventriculoperitoneal shunting for idiopathic intracranial hypertension. Neurology 2004;63:1314–1316.
83.
Stiebel-Kalish H, Kalish Y, Lusky M, Gaton DD, Ehrlich R, Shuper A: Puberty as a risk factor for less favorable visual outcome in idiopathic intracranial hypertension. Am J Ophthalmol 2006;142:279–283.
84.
Kesler A, Hadayer A, Goldhammer Y, Almog Y, Korczyn AD: Idiopathic intracranial hypertension: risk of recurrences. Neurology 2004;63:1737–1739.
85.
Smith JL: Whence pseudotumor cerebri? J Clin Neuro-ophthalmol 1985;5:55–56.
86.
Friedman DI, Jacobson DM: Idiopathic intracranial hypertension. J Neuro-ophthalmol 2004;24:138–145.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.